Rybelsus is now FDA-approved for managing cardiovascular health. Doctors say oral GLP-1s may reduce heart attack and stroke ...

In the recent SOUL trial, the GLP-1 drug reduced the risk of MACE by 14% over 4 years. Next up: a possible obesity indication ...

The age of the GLP-1 drug has reached yet another milestone, with the US Food and Drug Administration green-lighting Novo Nordisk's once-daily oral semaglutide pill to treat people at high risk of ...

A new analysis finds that the heart-protecting benefits of semaglutide are largely independent of its weight loss effects.

An experimental GLP-1/glucagon (GCP) dual receptor agonist from Eli Lilly and its Chinese partner Innovent has bested Novo Nordisk’s reigning GLP-1 semaglutide in a phase 3 study across both b | ...

This article was reviewed by Lynn Marie Morski, MD, JD. Does Ozempic® Cause Cancer? Key takeaways: Semaglutide — the active ...

This article was reviewed by Lynn Marie Morski, MD, JD. Ozempic Stomach Paralysis: Risks & Treatments Key takeaways: Stomach ...

This article was reviewed by Lynn Marie Morski, MD, JD. How Long Does Ozempic® Stay in Your System? Key takeaways: Ozempic® ...

Dr Reddy's Labs may face an 8-12 month delay in launching its semaglutide generic in Canada after receiving a non-compliance ...